Efficacy and Safety of JT001 (VV116) Compared With Paxlovid

Inclusion Criteria: * Participants who have a positive SARS-CoV-2 test result. * Participants who have one or more mild or moderate COVID-19 symptoms, and total symptom score ≥ 2. * Participants who have one or more of the following requirements: ≤7 days from the first positive test for SARS-COV-2 virus infection to the first dose; ≤5 days from the first onset of COVID-19 symptoms to the first dose; SARS-CoV-2 Ct Value ≤20 within 24 hours prior to the first dose. * Participants who satisfy one or more than one of the following high risks for progression to severe COVID-19, including death. * Participants who must agree to adhere to contraception restrictions. * Participants who understand and agree to comply with planned study procedures. * Participants or legally authorized representatives can give written informed consent approved by the Ethical Review Board governing the site. * Capable of giving signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Exclusion Criteria: * Participants who are judged by the investigator as likely to progress to severe/critical COVID-19 prior to randomization. * Participants who have SpO2≤93% on room air at sea level or PaO2/FiO2≤ 300, or respiratory rate ≥30 per minute. * Participants who require mechanical ventilation or anticipated impending need for mechanical ventilation. * Participants who have eye disease. * Participants who have any of the following conditions when screening: ALT or AST\>1.5 ULN; e GFR \<60 mL/min. * Participants who have known allergies to any of the components used in the formulation of the interventions. * Any medical condition, which in the opinion of the Investigator, will compromise the safety of the participant. * Participants who have received a SARS-CoV-2 monoclonal antibody treatment or prevention, or antiviral treatment (including the investigational treatment). * Participants who have received convalescent COVID-19 plasma treatment. * Participant's use of contraindicated drugs in the Package Insert of Nirmatrelvir Tablet/Ritonavir Tablets. * Participants who have participated, within the last 30 days, in a clinical study involving an investigational intervention. If the previous investigational intervention has a long half-life, 5 half-lives or 30 days, whichever is longer, should have passed. * Participants who are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study. * Female who is pregnant or breast-feeding or plan to be pregnant within this study period. * Male whose wife or partner plan to be pregnant within this study period.